Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medibeacon Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals area. This count is identical to the number of 4 distinct examiners, while the portfolio spans 3 distinct art units. CLARK, AMY LYNN is the busiest examiner with 1 pending office action.
The presence of 3 distinct art units indicates that the company's pharmaceutical innovations are being evaluated across several specialized technical classifications. With 1 pending office action assigned to the busiest examiner, the remaining matters are distributed among other individuals and units at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.1% | +31.2% |
| RALIS, STEPHEN J | 1 | 33.5% | +42.3% |
| MEJIAS, SAMANTHA LEE | 1 | 46.4% | +40.9% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18108879 | METHOD FOR NON-INVASIVE MONITORING OF FLUORESCENT TRACER AGENT WITH BACKGROUND SEPARATION CORRECTIONS | RALIS, STEPHEN J | 16d overdue |
| 18520826 | SYNTHESIS OF SUBSTITUTED PYRAZINES | CLARK, AMY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18108879 | METHOD FOR NON-INVASIVE MONITORING OF FLUORESCENT TRACER AGENT WITH BACKGROUND SEPARATION CORRECTIONS | RALIS, STEPHEN J | 16d overdue |
| 18520826 | SYNTHESIS OF SUBSTITUTED PYRAZINES | CLARK, AMY LYNN | — |
| 17708789 | METHODS OF MONITORING MUCOSAL HEALING | MEJIAS, SAMANTHA LEE | — |
| 17523659 | SUBCUTANEOUS AND INTRAMUSCULAR ADMINISTRATION OF PYRAZINE COMPOUNDS | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1628 | 1 |
| 3992 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18520826 | SYNTHESIS OF SUBSTITUTED PYRAZINES | CLARK, AMY LYNN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18108879 | METHOD FOR NON-INVASIVE MONITORING OF FLUORESCENT TRACER AGENT WITH BACKGROUND SEPARATION CORRECTIONS | RALIS, STEPHEN J | 3992 | §103§112Other | Non-Final OA | 16d overdue | Pending | Feb 13, 2023 |
| 17708789 | METHODS OF MONITORING MUCOSAL HEALING | MEJIAS, SAMANTHA LEE | 1618 | §103§112DP | Non-Final OA | — | Pending | Mar 30, 2022 |
| 17523659 | SUBCUTANEOUS AND INTRAMUSCULAR ADMINISTRATION OF PYRAZINE COMPOUNDS | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | — | Pending | Nov 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial